A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Terns Pharmaceuticals, Inc.
TERN
$1.9B
Mkt Cap
Terns Pharmaceuticals, Inc. (TERN) has a 5-year average return on invested capital (ROIC) of -25.6%. This is below average and may indicate limited pricing power.
Terns Pharmaceuticals, Inc. (TERN) has a market capitalization of $4.6B. It is classified as a mid-cap stock.
Terns Pharmaceuticals, Inc. (TERN) does not currently pay a regular dividend.
Terns Pharmaceuticals, Inc. (TERN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Terns Pharmaceuticals, Inc. (TERN) generated $-49 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Terns Pharmaceuticals, Inc. (TERN) reported earnings per share (EPS) of $-1.67 in its most recent fiscal year.
The Ledger Terminal provides 3 years of financial data for Terns Pharmaceuticals, Inc. (TERN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Company Overview We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are advancing multiple drug candidates we believe have the potential to deliver improved clinical outcomes in the target indication as either single-agent or combination therapies. The most advanced product candidates in our pipeline – TERN-701, TERN-601 and TERN-501 – were internally discovered. Additionally, we have an ongoing discovery effort for the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity, which have the potential to be combined with glucagon-like peptide-1 (GLP-1) receptor agonists, such as TERN-601.
| Metric | TTM | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 |
| Net Income | -96M | -60M | -50M | - |
| EPS | $-0.92 | $-1.67 | $-2.21 | $-102.93 |
| Free Cash Flow | -82M | -49M | -42M | -30M |
| ROIC | -8.5% | -21.6% | -29.7% | - |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | - | - | -0.14 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -110M | -62M | -50M | -37M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -9.6% | - | - | - |
| Shares Outstanding | 112M | 36M | 23M | 0M |
| Metric | ||||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 28M | 31M | 40M | 78M |
| SG&A | 9.0M | 20M | 22M | 32M |
| EBIT | -37M | -50M | -62M | -110M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | N/A | -50M | -60M | -96M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | N/A | -29.7% | -21.6% | -8.5% |
| ROE | N/A | N/A | N/A | -9.6% |
| ROA | N/A | -38.5% | -26.5% | -9.4% |
| Cash Flow | ||||
| Op. Cash Flow | -30M | -42M | -49M | -82M |
| Free Cash Flow | -30M | -42M | -49M | -82M |
| Owner Earnings | -32M | -50M | -60M | -96M |
| CapEx | 584K | 340K | 275K | 0 |
| Maint. CapEx | 394K | 512K | 484K | 90K |
| Growth CapEx | 190K | 0 | 0 | 0 |
| D&A | 394K | 512K | 484K | 90K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.7M | 8.1M | 11M | 13M |
| Debt Repayment | 0 | 13M | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -58M | -153M | -281M | -1.0B |
| Cash & Equiv. | 75M | 48M | 143M | 1.0B |
| Long-Term Debt | 17M | 0 | 544K | 544K |
| Debt/Equity | -0.14 | N/A | N/A | 0.00 |
| Interest Coverage | -3.5 | N/A | N/A | N/A |
| Equity | -117M | N/A | N/A | 1.0B |
| Total Assets | 92M | 168M | 287M | 1.0B |
| Total Liabilities | 24M | N/A | N/A | 19M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -132M | -182M | -242M | -518M |
| Working Capital | 68M | 160M | 277M | 1.0B |
| Current Assets | 91M | 167M | 285M | 1.0B |
| Current Liabilities | 23M | 6.8M | 8.5M | 16M |
| Per Share Data | ||||
| EPS | -102.93 | -2.21 | -1.67 | -0.92 |
| Owner EPS | -94.50 | -2.22 | -1.67 | -0.85 |
| Book Value | -347.97 | N/A | N/A | 8.96 |
| Cash Flow/Share | -88.32 | -1.84 | -1.36 | -0.86 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.3M | 22.7M | 36.1M | 112.3M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -44.5 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 4.6 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -27.9% | -14.9% | -1.8% |
| Market Cap | N/A | 151M | 331M | 4.6B |
| Avg. Price | N/A | 13.64 | 4.16 | 40.92 |
| Year-End Price | N/A | 6.66 | 9.17 | 40.92 |
Terns Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.